Clinical trial NCT06614894: An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III
Official title: An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
PHASE3
Conditions: Sanfilippo Syndrome
MPS3
Lead sponsor: Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Sponsor class: OTHER
Collaborators: name: Team Sanfilippo
First posted: 2024-09-26
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: A Non-randomized (single arm) clinical trial where all participants will receive the same experimental therapy and undergo the same dose escalation plan. All participants will be followed over time to observe their response related to safety and effectiveness.
Primary purpose: TREATMENT

Brief summary: A dose escalation study to evaluate the safety, tolerability, and pharmacologic properties of Ambroxol in adult participants with Sanfilippo disease(s) (MPS3).

Detailed description: This is a dose escalation study in which open label Ambroxol 30mg (study drug) will be administered to adult patients with Sanfilippo Disease (MPS3). Administration route of study drug will be either crushed and mixed with soft foods or as an Ambroxol suspension through a feeding tube, if applicable.

Study Timeline - Screening: 4 weeks (28 days) Treatment Period: 52 weeks Post-Treatment (after Week 52): 4 weeks withdrawal/safety follow-up period

Patients will be screened at which point a thorough review of the Informed Consent form will be completed, sNFL levels, urinary GAGs, and serum HS results/data from the previous 12 months will be reviewed, urine and blood will be collected, complete questionnaires, Motor skills assessments, and evaluation by the Principal Investigator (PI).

Eligible patients will proceed to receive the initial Ambroxol dose of 9mg/kg/day (maximum dose of 150 mg TID) divided into three equal doses per day, on-site. Other assessments including blood and urine collection, ECG, motor skills assessments, hearing test, questionnaires, and evaluation by the PI will be completed.

Following the first day of dosing, a virtual visit will be performed via Telemedicine within 1 week of dose start to assess safety.

At Weeks 12 and 24, enrolled patients will return to site for Ambroxol dose escalation to 18mg/kg/day (max dose of 300 mg TID) and 27mg/kg/day (max dose of 1350 mg/day), respectively. Assessments including blood and urine collection, ECG, motor skills assessments, hearing test, questionnaires, and evaluation by the PI will be completed at these visits.

Telemedicine visits will take place at Weeks 13 and 25, to assess safety.

At Week 36, a safety visit will be performed in which blood and urine will be collected.

At Week 52, end of study assessments will be completed which includes blood and urine collection, motor skills assessments, hearing test questionnaires, and evaluation by the PI will be conducted and treatment will be stopped.

A safety follow-up visit will be done 4 weeks after Week 52 visit is completed in which the patient will be evaluated by the PI.

Eligibility criteria: Inclusion Criteria:

1. IRB - approved informed consent/assent signed by subject and/or parent(s) or legal guardian(s).
2. Genetically confirmed diagnosis of MPS III disease.
3. Genomic DNA analysis demonstrating a homozygous or compound heterozygous pathogenic variants in SGSH (type A), NAGLU (type B), HGSNAT (type C), or GNS (type D) genes. Type E will not be studied.
4. Elevated excretion of urinary GAGs and/or serum HS (if no historical data is available, screening GAGs and serum HS values will be utilized to assess inclusion criteria).
5. Male or female; eighteen years of age and older, who is able to take Ambroxol Hydrochloride orally.
6. Negative urine pregnancy test at screening for female subjects with child-bearing potential.
7. The subject is willing to abstain from consumption of grapefruit, grapefruit juice, or grapefruit containing products for 72 hours prior to administration of the first dose of Ambroxol and for the duration of the treatment period.

Exclusion Criteria:

1. Unwilling or unable to follow protocol requirements as per principal investigator.
2. Any serious or chronic medical illness, including significant cardiac or severe debilitating pulmonary disease.
3. Poorly controlled seizures, defined as more than one seizure per day for the past 6 months.
4. Medications identified as a strong inducers or inhibitors of CYP3A, and changing to another alternative drug to treat the condition would place the subject at undue risk.
5. Any medical condition that, in the opinion of the PI, would make the subject unsuitable to participate in the study.
6. Inability to cooperate for clinical and safety data collection.
7. Known hypersensitivity to Ambroxol or any of its excipients.
8. Use of genistein or Miglustat within one week of starting screening.
9. Evidence of hepatitis B or hepatitis C infection upon serological testing at screening.
10. Currently participating in another clinical trial or has completed an interventional trial less than 2 weeks prior to screening visit.
11. The subject has received strong inducers (Note: eg, herbal supplements) or inhibitors of CYP3A within 15 days or 5 half-lives from screening, whichever is longer, prior to enrollment. This also includes the consumption of grapefruit, grapefruit juice, or grapefruit containing products within 72 hours of starting Ambroxol administration.

Primary outcomes:
measure: Safety and Tolerability
timeFrame: From baseline to 52 weeks
Secondary outcomes:
measure: Changes in physical examination from baseline in motor capabilities and disease state: Physician (Clinician) Global Impression of Change
timeFrame: From baseline to 52 weeks
measure: Change from baseline in EQ-5D-5L™ or EQ-5D-Y™
timeFrame: From baseline to 52 weeks
measure: Change from baseline in VABS-III age equivalent scores (AEqs)
timeFrame: From baseline to 52 weeks
measure: Assessment of Pharmacokinetics of Ambroxol in subjects with MPS III
timeFrame: From baseline to 52 weeks
measure: Assessment of Pharmacokinetics of Ambroxol in subjects with MPS III
timeFrame: From baseline to 52 weeks
measure: Assessment of Pharmacokinetics of Ambroxol in subjects with MPS III
timeFrame: From baseline to 52 weeks
measure: Assessment of Pharmacokinetics of Ambroxol in subjects with MPS III
timeFrame: From baseline to 52 weeks
measure: Assessment of Pharmacodynamics of Ambroxol in subjects with MPS III
timeFrame: From baseline to 52 weeks
measure: Assessment of Pharmacodynamics of Ambroxol in subjects with MPS III
timeFrame: From baseline to 52 weeks
measure: Change from baseline in Timed up and go (TUG) test
timeFrame: From baseline to 52 weeks
measure: Change from baseline in 10-meter walk test
timeFrame: From baseline to 52 weeks
measure: Change from baseline in SBRS
timeFrame: From baseline to 52 weeks
Other outcomes:
Locations:
city: Fairfax
country: United States
facility: Lysosomal & Rare Disorders Research & Treatment Center, Inc.
state: Virginia
Study officials:
affiliation: Lysosomal & Rare Disorders Research & Treatment Center, Inc.
name: Ozlem Goker-Alpan, MD
role: PRINCIPAL_INVESTIGATOR
References: